Efficacy of Everolimus for Treating Renal Angiomyolipoma with Inferior Vena Cava Thrombus Associated with Tuberous Sclerosis: A Case Report

Abstract

Here we report a case of 57-year-old woman with renal angiomyolipoma associated with tuberous sclerosis complex involving inferior vena cava thrombus. We could perform less invasive nephrectomy with thrombectomy because everolimus administration reduced the inferior vena cava thrombus. To the best of our knowledge, this is the first report the use of everolimus before performing surgery to treat renal angiomyolipoma with inferior vena cava thrombus.

Effectiveness of everolimus for sporadic renal angiomyolipoma with inferior vena cava thrombus: A case report

“…Several case reports showed the efficacy of everolimus even for a large AML. 2 In TSC patients, 85% of them have TSC1 and TSC2 genetic defects, leading to the deficiency of a protein that regulates mTORC1 activation. 3 Everolimus directly inhibits mTORC1 and disrupts TSC-AML cell growth through the mTOR pathway.…”

Angiomiolipoma renal con invasión de vena renal y vena cava inferior. Presentación de un caso y revisión de la literatura

“…3,4 Asimismo, en el caso de los AML irresecables y/o malignos, Ikarashi y col., demostraron la efectividad de los inhibidores de mTOR (everolimus, sirolimus…) como tratamiento coadyuvante para reducir la masa y convertirla en abordableresecable quirúrgicamente. 7 Describimos un caso raro de tumor renal diagnosticado mediante TAC a partir del hallazgo de trombo venoso con ecografía y resonancia, sin verse en esas pruebas la masa renal origen del trombo. El manejo se realizó mediante nefrectomía y trombectomía abierta, con anatomía patológica compatible con angiomiolipoma clásico con trombo venoso graso.…”

Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report

“…There is no established treatment for unresectable cases; however, mTOR inhibitors have been reported to be effective in AML associated with tuberous sclerosis. [4][5][6][7][8][9] There have also been reports of responses to tyrosine kinase inhibitors in some cases. [7][8][9][10][11][12][13] Unlike RCC, intravenous extension to inferior vena cava (IVC) is extremely rare in EAML.…”